Overview

Study Of Dalbavancin Drug Levels Achieved In Hospitalized Adolescents Who Are Receiving Antibiotic Therapy For Bacterial Infections

Status:
Completed

Trial end date:
2009-07-01

Target enrollment:

Participant gender:

Summary

Adolescent subjects hospitalized for the treatment of bacterial infections will be given 1 gram of dalbavancin through their veins and levels of dalbavancin in blood and urine will be measured at different time points. Safety labs will also be checked on a regular basis to assess the safety of dalbavancin.

Phase:

Phase 1

Details

Lead Sponsor:

Pfizer

Treatments:

Dalbavancin
Teicoplanin